ImproveR International (BI-001-IM)

European Registry of Consecutive Patients Undergoing PCI Evaluating the Use of the Thrombin-specific Anticoagulant Bivalirudin With Focus on Patient Selection, Convenience and Safety Aspects.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00290849

Enrollment

4000

Registered

2006-02-13

Start date

2005-03-31

Completion date

2007-09-30

Last updated

2012-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombin-specific Anticoagulant Bivalirudin During Percutaneous Coronary Intervention (PCI)

Brief summary

The objectives of this registry are to assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting. In particular, data will be collected to analyze experiences of bivalirudin use in respect to the following objectives; * examine the aspects of safety and effectiveness of bivalirudin * gain experience regarding the characteristics of patients in bivalirudin treatment * evaluate the handling of bivalirudin and its practicality

Interventions

DRUGBivalirudin

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

\> 18 years, undergoing planned or urgent PCI with the intention to use bivalirudin as anticoagulant, written informed concent to entry of data information registry.

Exclusion criteria

None

Design outcomes

Primary

Measure	Time frame
To assess the use of the thrombin-specific anticoagulant bivalirudin during percutaneous coronary intervention (PCI) in a real life setting. In particular, data will be collected to analyze experiences of bivalirudin use in respect to the following;	—
•examine the aspects of safety and effectiveness of bivalirudin	—
•gain experience regarding the characteristics of patients in bivalirudin treatment	—
•evaluate the handling of bivalirudin and its practicality.	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026